Contributions
Abstract: PB1458
Type: Publication Only
Session title: Aggressive Non-Hodgkin lymphoma - Clinical
Background
Myeloid differentiation primary response 88 (MYD88) is a common adaptor protein that is responsible for signaling from several receptors; is encoded by the MYD88 gene. [1].
Aims
Aim: We aimed to document the level of MYD88 expression, and their associations with clinicopathological parameters in CNS Lymphomas.
Methods
Methods: A total of 9 patients were included in the study. MYD88 protein expression was evaluated by immunohistochemistry (IHC) using two different scoring systems. All samples were diagnosed and selected by a hematopathologist. Tissue samples were collected from all patients before treatment.
MYD88 cytoplasmic expression was classified as four categories according to the staining intensity on a scale from 0 to 3 as follows: 0, no reaction; 1, weak reaction; 2, moderate reaction; and 3, strong reaction. This classification was called the first classification model. In the second classification model, the extent of staining scored as 0 (0% of tumor area stained), 1 ( < 10%), 2 (10–50%), or 3 ( > 50%) [2] . Staining intensity and the percentage of tumor cell positivity were evaluated and recorded by a hematopathologist .
Results
A majority of the patients in our CNSL cohort had an ABC-like immunophenotype, as has been previously reported [3]. MYD88 protein expression was seen in 8/9 cases (88,8%) and varied widely by intensity and density of expression. Five patients (55,5%) showed high-level MYD88 expression.1 patient didn’t show protein expression. 3 of patient (patient 2,3and 9) dead after the diagnose who shows low expression of MYD 88 .
Conclusion
Conclusion: MYD 88 protein expression was found both of primary and secondary CNS lymphomas regardless of lymphoma subtype. Further studies are needed for its relationship with prognosis.
Keyword(s): CNS lymphoma, Diffuse large B cell lymphoma
Abstract: PB1458
Type: Publication Only
Session title: Aggressive Non-Hodgkin lymphoma - Clinical
Background
Myeloid differentiation primary response 88 (MYD88) is a common adaptor protein that is responsible for signaling from several receptors; is encoded by the MYD88 gene. [1].
Aims
Aim: We aimed to document the level of MYD88 expression, and their associations with clinicopathological parameters in CNS Lymphomas.
Methods
Methods: A total of 9 patients were included in the study. MYD88 protein expression was evaluated by immunohistochemistry (IHC) using two different scoring systems. All samples were diagnosed and selected by a hematopathologist. Tissue samples were collected from all patients before treatment.
MYD88 cytoplasmic expression was classified as four categories according to the staining intensity on a scale from 0 to 3 as follows: 0, no reaction; 1, weak reaction; 2, moderate reaction; and 3, strong reaction. This classification was called the first classification model. In the second classification model, the extent of staining scored as 0 (0% of tumor area stained), 1 ( < 10%), 2 (10–50%), or 3 ( > 50%) [2] . Staining intensity and the percentage of tumor cell positivity were evaluated and recorded by a hematopathologist .
Results
A majority of the patients in our CNSL cohort had an ABC-like immunophenotype, as has been previously reported [3]. MYD88 protein expression was seen in 8/9 cases (88,8%) and varied widely by intensity and density of expression. Five patients (55,5%) showed high-level MYD88 expression.1 patient didn’t show protein expression. 3 of patient (patient 2,3and 9) dead after the diagnose who shows low expression of MYD 88 .
Conclusion
Conclusion: MYD 88 protein expression was found both of primary and secondary CNS lymphomas regardless of lymphoma subtype. Further studies are needed for its relationship with prognosis.
Keyword(s): CNS lymphoma, Diffuse large B cell lymphoma